Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32659747 | 1.00 | LMNA (0.47) | LMNAMAPTADORA3ADORA2AADORA1 | |
| SCHEMBL23630568 | 0.92 | MAPT (0.49) | LMNAMAPTRETADKSRC | |
| SCHEMBL32659760 | 0.92 | MAPT (0.49) | LMNAMAPTRETADKSRC | |
| SCHEMBL32659778 | 0.91 | MAPT (0.42) | LMNAMAPTADORA3ADORA2AADORA1 | |
| SCHEMBL23630576 | 0.91 | MAPT (0.42) | LMNAMAPTADORA3ADORA2AADORA1 | |
| SCHEMBL23630520 | 0.85 | SRC (0.41) | LMNAMAPTRETSRCABL1 | |
| SCHEMBL32659757 | 0.85 | SRC (0.41) | LMNAMAPTRETSRCABL1 | |
| SCHEMBL23630546 | 0.82 | PRKD3 (0.42) | MAPTRETADKSRCABL1 | |
| SCHEMBL32659767 | 0.82 | PRKD3 (0.42) | MAPTRETADKSRCABL1 | |
| SCHEMBL23630557 | 0.80 | PRKD3 (0.41) | LMNAMAPTRETADKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522606-B2 | Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy | UNIVERSITY OF WASHINGTON (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| WO-2021142170-A1 | MODIFIED PYRROLO- AND PYRAZOLO- PYRIMIDINES FOR PROSTATE CANCER THERAPY | UNIVERSITY OF WASHINGTON (US) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | PDK2, PDK1, PC | LMNA 4329/4885MAPT 1534/4885ADORA3 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.